Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Guerrero-Zotano, A; Belli, S; Zielinski, C; Gil-Gil, M; Fernandez-Serra, A; Ruiz-Borrego, M; Gil, EMC; Pascual, J; Munoz-Mateu, M; Bermejo, B; Vila, MM; Anton, A; Murillo, L; Nissenbaum, B; Liu, Y; Herranz, J; Fernandez-Garcia, D; Caballero, R; Lopez-Guerrero, JA; Bianco, R; Formisano, L; Turner, N; Martin, M.

CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2-Metastatic Breast Cancer

CLINICAL CANCER RESEARCH. 2023; 29(8): 1557-1568 Nº de citas: 46 [doi:10.1158/1078-0432.CCR-22-2206]

Canovas, MS; Garay, DF; Adoamnei, E; Garcia, EG; Robles, JL; Lavin, DC; de Castro, EM; Balea, BC; Fernandez, AG; Perez, IF; Arias, AF; Suarez, N; Verduguez, TQ; de Mena, ML; Rodriguez, L; Gutierrez, D; de Soiginie, AMMF; Adrian, SG; Perez, AIF; Heredia, MJD; Lerma, AM; Luque, R; Rubi, MM; Blanco, ABR; Escobar, IG; Mendiola, J; Martin, AJM.

Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group

Clinical & Translational Oncology. 2023; 25(10): 3021-3031 Nº de citas: 3 [doi:10.1007/s12094-023-03171-z]

Hecht, JR; Raman, SS; Chan, A; Kalinsky, K; Baurain, JF; Jimenez, MM; Garcia, MM; Berger, MD; Lauer, UM; Khattak, A; Carrato, A; Zhang, Y; Liu, K; Cha, E; Keegan, A; Bhatta, S; Strassburg, CP; Roohullah, A.

Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases

ESMO Open. 2023; 8(2): Nº de citas: 29 [doi:10.1016/j.esmoop.2023.100884]

Vazquez, JC; Antolin, S; Ruiz-Borrego, M; Servitja, S; Alba, E; Barnadas, A; Lluch, A; Martin, M; Rodriguez-Lescure, A; Sola, I; Bonfill, X; Urrutia, G; Sanchez-Rovira, P.

Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis

Clinical & Translational Oncology. 2023; 25(4): 941-958 Nº de citas: 6 [doi:10.1007/s12094-022-02998-2]

Conde-Moreno, AJ; Gonzalez-Del-Alba, A; Lopez-Campos, F; Lopez, CL; Requejo, OH; Carpeno, JD; Chicas-Sett, R; Arias, LD; Montero-Luis, A; Perez, AR; Font, EF; Arija, JAA.

Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer

Clinical & Translational Oncology. 2023; 25(4): 897-911 Nº de citas: 2 [doi:10.1007/s12094-022-03019-y]

Perez, AR; Font, EF; Chicas-Sett, R; Montero-Luis, A; Arias, LD; Gonzalez-Del-Alba, A; Lopez-Campos, F; Lopez, CL; Requejo, OH; Conde-Moreno, AJ; Arija, JAA; Carpeno, JD.

Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer

Clinical & Translational Oncology. 2023; 25(4): 882-896 [doi:10.1007/s12094-022-03011-6]

Bravo-Anguiano, Y; Echavarria-Iniguez, A; Madrigal-Lkhou, E; Munoz-Martin, A.

Cancer-associated stroke: a study of prevalence and predictors among ischaemic stroke patients

REVISTA DE NEUROLOGIA. 2023; 76(6): 189-195 Nº de citas: 2 [doi:10.33588/rn.7606.2022414]

Ortiz, A; Quiroga, B; Díez, J; Martín, FJES; Ramirez, L; Maraver, MP; Asensio, MLMB; Arija, JAA; Fernández, JLAO; Córdoba, R; Muntó, FB; Hidalgo, MJC; Reverter, JC; Plasencia-Rodríguez, C; Gómez, JC; Guijarro, C; Guerrero, MDMF; de Sequera, P.

The Spanish Scientific Societies before the ESC 2021 guidelines on vascular disease prevention: Generalizing the measurement of albuminuria to identify vascular risk and prevent vascular disease

NEFROLOGIA. 2023; 43(2): 245-250 Nº de citas: 12

Toledano-Fonseca, M; Gomez-Espana, MA; Elez, E; Gravalos, C; Garcia-Alfonso, P; Rodriguez, R; Losa, F; Diaz, IA; Grana, B; Valladares-Ayerbes, M; Garcia-Ortiz, MV; Polo, E; Salgado, M; Rivera, F; Safont, MJ; Salud, A; Ruiz-Casado, A; Tabernero, JM; Riesco, MC; Rodriguez-Ariza, A; Aranda, E.

A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients

BIOMEDICINE & PHARMACOTHERAPY. 2023; 159: Nº de citas: 10 [doi:10.1016/j.biopha.2023.114272]

Herzog, TJ; Pignata, S; Ghamande, SA; Rubio, MJ; Fujiwara, K; Vulsteke, C; Armstrong, DK; Sehouli, J; Coleman, RL; Gabra, H; Scambia, G; Monk, BJ; Arranz, JA; Ushijima, K; Hanna, R; Zamagni, C; Wenham, RM; Gonzalez-Martin, A; Slomovitz, B; Jia, Y; Ramsay, L; Tewari, KS; Weil, SC; Vergote, IB.

Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

Gynecologic Oncology. 2023; 170: 300-308 Nº de citas: 17 [doi:10.1016/j.ygyno.2023.01.003]

Gonzalez-Cao, M; Puertolas, T; Martinez-Vila, C; Carrera, C; Seral, CM; Rodriguez-Jimenez, P; Sequero, S; Cerezuela-Fuentes, P; Ochoa, RF; Munoz, E; Basa, MA; Martin-Liberal, J; Soria, A; Moreno, JFR; Marquez-Rodas, I; Criado, PL; Manzano, JL; Lopez-Castro, R; De Miguel, PA; Villalobos, L; Algarra, SM; Gonzalez-Barrallo, I; Boada, A; Castano, AG; Puig, S; Crespo, G; Fra, PL; Zamora, CA; Rodriguez, MF; Valles, L; Drozdowskyj, A; Gardeazabal, J; Fernandez-Morales, LA; Rodrigo, A; Cruz, R; Yelamos, O; Rubio, B; Mujica, K; Provencio, M; Berrocal, A.

SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

Clinical & Translational Oncology. 2023; 25(3): 768-775 Nº de citas: 2 [doi:10.1007/s12094-022-02985-7]

Wong, SK; Blum, SM; Sun, XP; Da Silva IP; Zubiri, L; Ye, F; Bai, K; Zhang, KV; Ugurel, S; Zimmer, L; Livingstone, E; Schadendorf, D; Serra-Bellver, P; Muñoz-Couselo E; Ortiz, C; Lostes, J; Huertas, RM; Arance, A; Pickering, L; Long, GV; Carlino, MS; Buchbinder, EI; Vazquez-Cortes, L; Jara-Casas, D; Marquez-Rodas, I; Gonzalez-Espinoza, IR; Balko, JM; Menzies, AM; Sullivan, RJ; Johnson, DB.

Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma

EUROPEAN JOURNAL OF CANCER. 2023; 181: 188-197 Nº de citas: 14 [doi:10.1016/j.ejca.2022.12.013]

Andric Z; Gálffy G; Cobo Dols M; Szima B; Stojanovic G; Petrovic M; Felip E; Vicente Baz D; Ponce Aix S; Juan-Vidal O; Szalai Z; Losonczy G; Calles Blanco A; Bernabe R; García Ledo G; Aguilar Hernández A; Duecker K; Zhou D; Schroeder A; Guezel G; Ciardiello F.

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC.

JTO Clinical and Research Reports. 2023; 4(2): 100461-100461 Nº de citas: 1 [doi:10.1016/j.jtocrr.2022.100461]

Vazquez, JC; Pinero, A; de Castro, FJ; Lluch, A; Martin, M; Barnadas, A; Alba, E; Rodriguez-Lescure, A; Rojo, F; Gimenez, J; Sola, I; Quintana, MJ; Bonfill, X; Urrutia, G; Sanchez-Rovira, P.

The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review

Clinical & Translational Oncology. 2023; 25(2): 417-428 Nº de citas: 4 [doi:10.1007/s12094-022-02953-1]

Bar J; Peled N; Schokrpur S; Wolner M; Rotem O; Girard N; Aboubakar Nana F; Derijcke S; Kian W; Patel S; Gantz-Sorotsky H; Zer A; Moskovitz M; Metro G; Rottenberg Y; Calles A; Hochmair M; Cuppens K; Decoster L; Reck M; Limon D; Rodriguez E; Astaras C; Bettini A; Häfliger S; Addeo A.

UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)

Journal of Thoracic Oncology. 2023; 18(2): 169-180 Nº de citas: 81 [doi:10.1016/j.jtho.2022.10.004]

Asleh, K; Lluch, A; Goytain, A; Barrios, C; Wang, XQ; Torrecillas, L; Gao, DX; Ruiz-Borrego, M; Leung, S; Bines, J; Guerrero-Zotano, A; Garcia-Saenz, JA; Cejalvo, JM; Herranz, J; Torres, R; de la Haba-rodriguez, J; Ayala, F; Gomez, H; Rojo, F; Nielsen, TO; Martin, M.

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

CLINICAL CANCER RESEARCH. 2023; 29(2): 389-400 Nº de citas: 21 [doi:10.1158/1078-0432.CCR-22-2191]

Vidal, J; Fernandez-Rodriguez, MC; Casadevall, D; Garcia-Alfonso, P; Paez, D; Guix, M; Alonso, V; Cano, MT; Santos, C; Duran, G; Elez, E; Manzano, JL; Garcia-Carbonero, R; Ferreiro, R; Losa, F; Pineda, E; Sastre, J; Rivera, F; Bellosillo, B; Tabernero, J; Aranda, E; Salazar, R; Montagut, C.

Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study

CLINICAL CANCER RESEARCH. 2023; 29(2): 379-388 Nº de citas: 36 [doi:10.1158/1078-0432.CCR-22-1696]

de Haas, SL; Slamon, DJ; Martin, M; Press, MF; Lewis, GD; Lambertini, C; Prat, A; Lopez-Valverde, V; Boulet, T; Hurvitz, SA.

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine plus pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

BREAST CANCER RESEARCH. 2023; 25(1): Nº de citas: 42 [doi:10.1186/s13058-022-01587-z]